The participations of the physicians on the diagnosis and treatments of antiphospholipid related pregnancy morbidities in Japan: from the result of nationwide survey.
Thromboses and pregnancy morbidities are major pathologies of antiphospholipid syndrome (APS). In general, rheumatologists or hematologists see APS thrombosis patients, and they often give advices for the treatments of APS-related pregnancy morbidities, such as measurements and interpretations of antiphospholipid antibodies(aPL).



To survey the approaches of physicians in Japan to the diagnosis and treatment of aPL-associated pregnancy morbidities.



The study group on the Health and Labour Sciences Research Grants sent a questionnaire to 550 board members of the Japan College of Rheumatology and the Japanese Society on Thrombosis and Hemostasis, and analyzed the responses.



The number of valid responses was 157 (28.5%). The number of pregnant women who were diagnosed as having APS was 118.7 patients/year in 53 of 157 hospitals (33.8%). With respect to aPL measurements, 128 out of 157 hospitals (81.5%) determined one or more anticardiolipin antibodies or β2GPI-dependent anticardiolipin antibodies with one or more lupus anticoagulants; however aPL tests of only 2 hospitals (1.3%) covered all aPLs defined in the classification criteria. The obstetricians were responsible for treatments in 33.1% to 42.3% of the hospitals. The treatment methods or duration of treatments did not reach to the general consensus.



The number of cases of aPL-related pregnancy complications that physicians have intervened was relatively small. There are considerable patients that are not diagnosed as having the disease due to insufficient aPL examinations. There were less involvement of physicians to the diagnosis and treatment of pregnant women with aPLs.
Department of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine.
Kenji
K
Oku
Atsuko
A
Murashima
Kazumasa
K
Oomura
Olga
O
Amengual
Toshiyuki
T
Bohgaki
Tetsuya
T
Horita
Shinsuke
S
Yasuda
Kayoko
K
Kaneko
Isao
I
Nakanishi
Kazuhisa
K
Nozawa
Mayumi
M
Sugiura-Ogasawara
Tatsuya
T
Atsumi
D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage; D016736:Antiphospholipid Syndrome / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D001241:Aspirin / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007564:Japan / Q000453:epidemiology; D009017:Morbidity; D011239:Prednisolone / Q000008:administration & dosage; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D011795:Surveys and Questionnaires; D014859:Warfarin / Q000008:administration & dosage
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D015415:Biomarkers; D014859:Warfarin; D006493:Heparin; D011239:Prednisolone; D001241:Aspirin